DiaGenic and GE Healthcare to develop blood-based test for mild cognitive impairment, a disorder associated with risk for Alzheimer’s Disease

Oslo – March 26th 2012
DiaGenic ASA [OSL:DIAG] today announced a research agreement to collaborate with GE Healthcare to develop a blood-based test using DiaGenic’s peripheral gene expression profiling in patients with mild cognitive impairment, a disorder associated with risk for Alzheimer’s Disease. The study would be used in conjunction with PET imaging to identify a blood based gene expression signature in these patients. The PET imaging agent, [18F] Flutemetamol, is currently in phase 3 development and is not yet approved by any regulatory authority.
Read more

What do you think about this article and us? Please leave a comment!